---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-25-000043"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T09:43:58.377158+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MacroGenics reports FY2024 net loss of $67M; discontinues vobra duo development

## Summary
- Net loss of $67.0M ($1.07 diluted EPS) for FY2024 vs. net loss of $9.1M ($0.15) in FY2023.
- Total revenue $150.0M, up from $58.7M in FY2023, driven by $85M milestone from Incyte.
- Cash, cash equivalents and marketable securities $201.7M at Dec 31, 2024; cash runway extended into H2 2026.
- Discontinuing further internal development of vobra duo; seeking partner; Phase 2 TAMARACK rPFS 9.5-10.0 months.
- LORIKEET Phase 2 fully enrolled (150 patients); LINNET Phase 2 in ovarian cancer expected mid-2025.

## SEC filing metadata
- accession: 0001125345-25-000043
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534525000043/0001125345-25-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534525000043/mgnx-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-25-000043
- JSON: https://secwatch.observer/filing/0001125345-25-000043.json
- Plain text: https://secwatch.observer/filing/0001125345-25-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.